Compare NAAS & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NAAS | LIXT |
|---|---|---|
| Founded | 2019 | 2005 |
| Country | China | United States |
| Employees | N/A | 4 |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.5M | 25.3M |
| IPO Year | 2017 | N/A |
| Metric | NAAS | LIXT |
|---|---|---|
| Price | $2.57 | $3.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.5K | ★ 36.4K |
| Earning Date | 03-31-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $378.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.64 |
| 52 Week High | $4.54 | $6.09 |
| Indicator | NAAS | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 52.14 |
| Support Level | $2.22 | $2.97 |
| Resistance Level | $3.43 | $3.30 |
| Average True Range (ATR) | 0.16 | 0.28 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 51.43 | 66.25 |
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.